Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial

Clinical and Experimental Rheumatology

Volumn 24, Issue 5, 2006, Pages 514-520

  Furuzawa Carballeda, Janette ^a   Fenutria Ausmequet, Rafael ^b   Gil Espinosa, Victor ^b   Lozano Soto, Francisco ^b   Teliz Meneses, Marco A ^a   Romero Trejo, Cecilia ^a   Alcocer Varela, Jorge ^a  

^a INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Biological therapy; Collagen PVP; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; C REACTIVE PROTEIN; CHLOROQUINE; COLLAGEN TYPE 1; COLLAGEN TYPE 1 PLUS POVIDONE; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PLACEBO; SALAZOSULFAPYRIDINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE PAIN; JOINT SWELLING; LONG TERM CARE; MALE; MORNING STIFFNESS; PAIN ASSESSMENT; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; VISUAL ANALOG SCALE;

ADULT; ANIMALS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COLLAGEN TYPE I; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; POVIDONE; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SWINE;

EID: 33845487090     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. CARDIEL MH, ROJAS-SERRANO J: Community based study to estimate prevalence, burden of illness and help seeking behaviour in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheumatol 2002; 20: 617-24.
2. DROSSAERS-BAKKER KW, de BUCK M, van ZEBEN D, ZWINDERMAN AH, BREEDVELD FC, HAZES JM: Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999; 42: 1854-60.
3. BAYRAK S, MITCHISON NA: Bystander suppression of murine collagen-induced arthritis by long-term nasal administration of a self type II collagen peptide. Clin Exp Immunol 1998; 113: 92-5.
4. BAGCHI D, MISNER B, BAGCHI M, KOTHARI SC, DOWNS BW, FAFARD RD, PREUSS HG: Effects of orally administered undenatured type II collagen against arthritic inflammatory diseases: a mechanistic exploration. Int J Clin Pharmacol Res 2002; 22: 101-10.
5. KALDEN JR, SIEPER J: Oral collagen in the treatment of rheumatoid arthritis. Arthritis Rheum 1998; 41: 191-4.
6. CHOY EHS, SCOTT DL, KINGSLEY GH, THOMAS S, MURPHY AGV, STAINES N, PANAYI GS: Control of rheumatoid arthritis by oral tolerance. Arthritis Rheum 2001; 44: 1993-7.
7. FURUZAWA-CARBALLEDA J, KRÖTZSCH E, ESPINOSA-MORALES R, ALCALÁ M, BARILE-FABRIS L: Subcutaneous administration of collagen-polyvinylpyrrolidone down-regulates IL-1β, TGF-β1, ELAM-1 and VCAM-1 expression in scleroderma skin lesions. Clin Exp Dermatol 2005; 30: 83-6.
8. AINOLA MM, MANDELIN JA, LILJESTRÖM MP, LI T-F, HUKKANEN MVJ, KONTTINEN YT: Pannus invasion and cartilage degradation in rheumatoid arthritis: Involvement of MMP-3 and interleukin-1β. Clin Exp Rheumatol 2005; 23: 644-50.
9. HITCHON CA, EL-GABALAWY HS: The histopathology of early synovitis. Clin Exp Rheumatol 2003; 21 (Suppl. 31): S28-S36.
10. FURUZAWA-CARBALLEDA J, ALCOCERVARELA J, DÍAZ DE LEÓN L: Collagen-PVP decreases collagen turnover in synovial tissue cultures from rheumatoid arthritis patients. Ann NY Acad Sci 1999; 878: 598-603.
11. FURUZAWA-CARBALLEDA J, ALCOCERVARELA J, DÍAZ DE LEÓN L: Mediators of inflammation are down-regulated meanwhile apoptosis is up-regulated in rheumatoid arthritis synovial tissue by polymerized-collagen. Clin Exp Immunol 2002; 130: 140-9.
12. PAUL HL: Activators and target genes of Rel/NF-kappa B transcription factors. Oncogene 1999; 18: 6853-66.
13. ZHANG H-G, HUANG N, LIU D et al.: Gene therapy that inhibits nuclear translocation of nuclear factor κB results in tumour necrosis factor α-induced apoptosis of human synovial fibroblasts. Arthritis Rheum 2000; 43: 1094-1105.
14. FURUZAWA CARBALLEDA J, CABRAL AR, ZAPATA-ZÚÑIGA M, ALCOCER-VARELA J: Subcutaneous administration of polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. An open-label pilot trial. J Rheumatol 2003; 30: 140-9.
15. ARNETT FC, EDWORTHY SM, BLOCH DA et al.: The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998; 31: 315-24.
16. KRÖTZSCH-GÓMEZ FE, FURUZAWA-CARBALLEDA J, REYES MÁRQUEZ R et al.: Cytokine expression is downregulated by collagen-polyvinilpyrrolidone in hypertrophic scars. J Invest Dermatol 1998; 111: 828-34.
17. CARDIEL MH, ABELLO-BANFI M, RUÍZ-MERCADO R, ALARCÓN-SEGOVIA D: How to measure health status in rheumatoid arthritis in non-English speaking patients: validation of aspanish version of the health assessment questionnaire disability index (Spanish HAQ-DI). Clin Exp Rheumatol 1993; 11: 117-21.
18. LARSEN A: How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies?. J Rheumatol 1995; 22: 1974-5.
19. VILLAVERDE V, BALSA A, CANTALEJO M et al.: Activity indices in rheumatoid arthritis. J Rheumatol 2000; 27: 2756-81.
20. FELSON DT, ANDERSON JJ, LANGE MLM, WELLS G, LAVALLEY MP: Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?. Arthritis Rheum 1998; 41: 1564-70.
21. WEISS RA: Xenografts and retroviruses. Science 1999; 285: 1221-2.
22. ROBINSON BV, SULLIVAN FM, BORZELLECA JF, SCHWARTZ: PVP. A critical review of the kinetics and toxicology of polyvinylpyrrolidone (Povidone). Lewis Publishers, Inc. 1990; 147-9.
23. van ZEBEN D, HAZES JM, ZWINDERMAN AH, CATS A, van DER VOORT EA, BREEDVELD FC: Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992; 51: 1029-35.
24. GIMFERRER I, FARNÓS M, CALVO M et al.: The accessory molecules CD5 and CD6 associate on the membrane of lymphoid T cells. J Biol Chem 2003; 278: 8564-71.
25. RAMOS-CASALS M, GARCÍA-CARRASCO FM, CALVO J et al.: High circulating levels of soluble scavenger receptors (sCD5 and sCD6) in patients with primary Sjögren's syndrome. Rheumatol 2001; 40: 1036-59.
26. ARINBJARNARSON A, JONSSON T, STEINSSON K et al.: IgA rheumatoid factor correlates with changes in B and T lymphocyte subsets and disease manifestations in rheumatoid arthritis. J Rheumatol 1997; 24: 269-74.
27. KLARESKOG L, van der HEIJDE D, de JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675-81.